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The  immune  response  to  numerous  antigens  administered  parenterally  can  be 
suppressed or reduced by prior oral treatment with the same antigen. This applies to 
both  particulate  (1,  2)  and  soluble  (3-5)  antigens.  The  immune  tolerance  thus 
produced is specific and can be shown to affect cell-mediated hypersensitivity (6)  as 
well as the production of specific antibody, including reaginic antibody (7, 8). 
Little is  known  about  the effects of antigen  ingestion  after immunization  by the 
parenteral route with the same antigen  (9).  The few published data suggest that the 
hypersensitive state is not altered (6), although there may be a  booster effect on IgE 
production  (10).  We  show  here  that  ingestion  of antigen  after  immunization  can 
prevent the secondary antibody response and interrupt reaginic antibody production. 
These findings may have important clinical applications. 
Materials and Methods 
Antigen.  Ovalbumin recrystallized  five times (Serva, Heidelberg, Federal Republic of Ger- 
many) was used for all immunization procedures. 
Animals and Immunization.  We used 3-mo-old mice of both sexes of the strains AKR, DBA/2, 
and C3H supplied by IFFA-CREDO (L'Arbresle, France).  Intraperitoneal immunization was 
carried out by injecting 1 mg of ovalbumin (OVA) in 0.5 ml of 0.15 N saline, without adjuvant. 
Oral administration of antigen was performed by gavage, the dose being 20 mg OVA in 0.2 ml 
0.15 N saline. 
Antibody Determinations.  Antibodies to OVA were measured by passive haemagglutination, 
using sheep erythrocytes coated with OVA as  described  by Avrameas et al.  (11). Reaginic 
antibodies of both IgE nd IgG1  types were detected by passive cutaneous anaphylaxis using 
male AKR mice at least  12 wk old (12). 
Results 
Abrogation of the SecondaTy Antibody Response by Repeated  Oral Administration  of 0 VA  to 
Mice Prevwusly Immunized Parenterally (Figs.  1-3).  Variable results were obtained when 
OVA was given orally during the interval between two intraperitoneal immunizations 
1  mo  apart,  the  effect  being  a  function  of the  number  of oral  doses  given.  No 
attenuation  of the secondary responses was seen after only one oral administration 
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Fro.  1.  Antibodies to ovalbumin in AKR mice as measured by passive haemagglutination in the 
following groups:  (A) sacrificed  11  d  after primary immunization with  1 mg OVA i.p.  (B) 20 mg 
orally on day  1,  1 mg OVA i.p. on day  15, and killed on day 26. (C)  1 mg OVA i.p. on days 1 and 
30, and killed on day 41.  (D)  1 mg OVA i.p. on days 1 and 30, 20 mg orally on day  15, and killed 
on day 41.  (E)  I  mg OVA i.p. on days  1 and 30, four consecutive doses of 20 mg OVA orally on 
days 15-18, and killed on day 41. (F)  1 mg OVA i.p. on days 1 and 30, 20 mg OVA orally on each 
of days  15-19 and 21-25  (total  10 doses), and killed on day 41.  Differences between groups: C  vs. 
D, not significant; C  vs. E  or F, P<  0.001;  E  vs. F, P<  0.02  (Student's t test). 
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Fro.  2.  Antibodies to ovalbumin in DBA/2 mice as measured by passive haemagglutination in the 
groups A through F  (groups as in Fig.  1). Differences between groups: C  vs. D  or E, not significant; 
C  vs. F, P<  0.01;  E  vs. F, P<  0.001. 
(group  D),  regardless  of the  strain.  AKR  mice  showed  definite reduction  in  the 
secondary antibody response when given four oral doses of OVA on days 15-18 after 
primary immunization (group E). This was not seen in DBA/2 and C3H mice. When 
OVA was given on  10 occasions (group F) after primary immunization (days 15-19 
and  21-25),  the secondary antibody response was  almost  completely abolished  in 
AKR and C3H mice, and a clear reduction in the response was observed in DBA/2. 
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F]o.  3.  Antibodies  to  ovalbumin  in  C3H  mice  as  measured  by  passive haemagglutination in 
groups A through F (groups as in Fig. t). Differences between groups: C vs. D or E is not significant; 
C  vs. F and F vs. E, P <  0.01. 
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FxG. 4.  Reaginic antibody  tlters  (IgE  (.)  and IgGl  (*)  to OVA in  AKR mice as measured by 
passive cutaneous anaphylaxis). (A)  titer on day  15 after immunization with 20 mg OVA orally; 
(]3)  titer  on  day  30  after  immunization  with  20  mg OVA  orally;  (C)  titer  on  day  30  after 
immunization with I mg OVA i.p. and one oral dose of 20 mg on day 15; (D) titer on day 30 after 
immunization with  1 mg OVA i.p. alone and 4 consecutive oral doses of 20 mg OVA on days 15- 
18;  (E) titer on day 30 after immunization with  1 mg OVA i.p. and  10 oral doses of 20 mg OVA 
given on days 15-19 and 21-25. IgE level differences between groups: B vs. C, not significant; B vs. 
D and D  vs. E, P<  0.05. IgGl level difference between groups B and C, P<  0.05. 
of One Oral Dose of 0 VA (Figs. 1-3).  When AKR mice were given 20 mg OVA orally 
15 d before intraperitoneal immunization with 1 mg OVA (no adjuvant), the antibody 
response was greatly augmented in the majority of eases (group B). This did not occur 
in DBA/2 or C3H mice. 
Repeated Administration of Oral 0 VA Diminishes Reaginic Antibody Production in Sensitized 
Animals  (Fig. 4).  AKR  mice  showed  an  IgE  reaginic  antibody  response  to  one 1 ,~) 76  LAFONT ET AL.  BRIEF  DEFINITIVE REPORT 
intraperitoneal injection of 1 mg OVA without adjuvant (group B). A single oral dose 
of 20  mg OVA  15  d  after intraperitoneal  sensitization  did  not  suppress  antibody 
production (group C) and occasionally induced IgG 1 synthesis. However, 4 oral doses 
of OVA on days  15-18  (group D), or  10 doses on days  15-19 and  21-25  (group E) 
abolished both IgE and IgG1 responses 30 d after parenteral immunization. A single 
oral dose of OVA did not provoke a  reaginic antibody response in AKR mice. 
Discussion 
It is difficult to induce immune tolerance after an initial immunization procedure 
(10,  13). Here  we  show  that  repeated  oral  administration  of  antigen  (OVA)  is 
necessary  to  prevent  secondary antibody  responses  in  mice previously parenterally 
immunized. This is in contrast with other studies  (4-8), and is at variance with the 
recent studies  that  failed to demonstrate suppression of the secondary response  (10, 
13).  They did not study the effect of repeated oral administration  of antigen.  It is, 
however, well established that repeated stimulation of Peyer's patch suppressor T  cells 
with OVA is necessary to suppress the effect of primary parenteral immunization  (8, 
14-17). The possibility of antibody blocking by increased intestinal absorption of the 
antigen  may be ruled  out  for two reasons.  (a)  Local antibodies  produced  after oral 
administration  of  antigens  markedly  decrease  its  absorption  (18).  (b)  The  oral 
administration  of larger doses  (25  rag/d)  and for a  longer period  (14 d)  of OVA in 
C3H mice resulted in a  nonsignificant  amount of circulating antigen when assessed 
by radioimmunoassay in a  time protocol very similar to our own (4). 
Our  results  varied  with  the  strain  of mouse  used,  as  previously  described  (19). 
Inconsistent results were obtained with  DBA/2  mice, good suppression was seen  in 
the C3H strain, and the best results were obtained using AKR mice, in which a clear 
reduction in the secondary response occurred with four doses of oral antigen. We have 
also noticed  that  suppression of a  primary response by prior ingestion  of antigen  is 
difficult to obtain in DBA/2 mice, but occurs readily in C3H and AKR (unpublished 
data). It therefore appears that induction  of tolerance is genetically determined and 
is identical for both primary and secondary responses. 
Our interest in the reaginic antibody response in AKR mice was prompted by the 
observation that all the animals were in anaphylactic shock for at least  1 h  after the 
second  intraperitoneal  dose of OVA at  day 30.  However, when  one oral  dose was 
given  15 d  after sensitization, 4 out of 10 mice went into shock, 3 of 10 died, and 3 
remained healthy. We found a  substantial IgE response 30 d  after primary immuni- 
zation,  although  the  dose  of OVA  was  quite  high  (1  mg)  and  none  of the  usual 
adjuvants necessary to elicit reaginic responses were used. An oral dose of 20 mg does 
not  provoke  reaginic  response  (Fig.  4,  group  A).  Other  authors  (20)  have  found 
reaginic responses with minute doses of OVA by the oral route. We have shown that 
one dose of oral OVA at day  15 after intraperitoneal sensitization does not diminish 
the IgE response at day 30, and may occasionally induce IgG1. However, when four 
oral doses of OVA are given on consecutive days  (days  15-18),  reaginic antibodies 
become almost undetectable in the serum at day 30. Similar results are obtained with 
10 oral doses on days 15-19 and 21-25. A new intraperitoneal sensitization at day 30 
does not provoke any shocks in AKR mice after 4 or 10 oral doses. 
We  have confirmed,  as  previously suggested  (21),  that  oral  ingestion  of antigen 
could reduce anaphylactic reactions in sensitized subjects. Recently, it has been shown LAFONT ET AL.  BRIEF DEFINITIVE REPORT  1577 
that repeated intraperitoneal injections of OVA can reduce reaginic antibody titers 1 
mo after sensitization (22). It therefore seems possible that desensitization occurs as a 
result of repeated exposure to relatively small amounts of absorbed antigen. 
The possible reduction  in intensity of a  secondary humoral response by repeated 
ingestion  of antigen  has  important  clinical  implications.  That  this  is more than  a 
theoretical possibility has been demonstrated by Bierme et al. (23), who reported the 
beneficial effect of feeding rhesus antigens to extremely immunized mothers. 
Summary 
We have investigated the possibility of oral administration of ovalbumin (OVA) to 
prevent  a  secondary antibody reponse and  interrupt  reaginic antibody production. 
Repeated feeding seems necessary for both. Quality of results was dependent  on the 
number of ingestions.  Differences in abrogation of antibody response between mice 
strains were observed. Best results were obtained with AKR mice, good suppression 
was seen in C3H strain, and inconsistent results were obtained with DBA/2.  10 OVA 
oral doses were necessary to prevent a  secondary antibody response in parenterally 
immunized mice, but 4 doses interrupted reaginic production in sensitized AKR mice. 
These  results  demonstrate  that  antigen  feeding  can  prevent  a  secondary antibody 
response and interrupt reaginic antibody production. 
Received  for publication 18 November 1981 and in revised  form 3 March 1982. 
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